Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Plummer

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Pageof 10